# Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

- Link: https://www.thailand-business-news.com/pr-news/antengene-to-present-latest-preclinical-results-of-atg-207-%ce%b1cd3-tgf-%ce%b2-bifunctional-fusion-protein-at-acr-2026
- Published: 2026-10-09T10:22:00+07:00
- Author: PR Newswire

|   |

SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ — Antengene Corporation Limited(**"
Antengene"**, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech
company dedicated to discovering, developing and commercializing first-in-class 
and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological
malignancies indications, today announced that **it** **will release the latest 
preclinical results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) in a Poster
Presentation at the 2026 American College of Rheumatology (ACR) Annual Meeting, 
taking place from November 6****th**** to November 11****th**** in Orlando, Florida,
the United States. **ATG-207 is our proprietary, globally first-in-class αCD3-TGF-
β bifunctional fusion protein being developed for the treatment of T cell–mediated
autoimmune diseases.

**Details of the Poster Presentation**

**Title: **Preclinical Characterization of ATG-207, a Masked and TGFβRIII-Biased
αCD3-TGF-β Bi-specific Fusion Protein, for the Treatment of T cell-related Autoimmune
Diseases
**Abstract Number: **0974**Session:  **Poster Session B, (0965-0976) T 
Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster B**Date: **Monday,
November 9, 2026**Time: **10:30 AM – 12:30 PM (Eastern Time)           11:30 PM,
November 9 – 01:30 AM, November 10 (Beijing Time)

**Study Overview: **

 ◦ T cell–mediated autoimmune diseases are characterized by persistent pathogenic
   effector T-cell activity and inadequate regulatory T-cell (Treg) function, resulting
   in loss of durable immune tolerance. Therapies that restore immune balance through
   Treg induction are therefore of significant interest. Transforming growth factor-
   beta (TGF-β) is a pivotal cytokine for Treg differentiation and maintenance, 
   yet its systemic delivery is clinically restricted by broad receptor engagement
   that raises significant safety concerns.
 ◦ ATG-207 was developed by introducing a peptide-masked and TGFβRIII-biased TGF-
   β domain to an anti-CD3 antibody. _In vitro _assays were performed to assess 
   TGFβ receptor binding affinity, TGFβ signaling, T cell activation/exhaustion,
   T cell receptor (TCR) expression, cytokine release and regulatory T cell induction.
   _In vivo_ efficacy and pharmacodynamic effects were evaluated in murine models
   of T cell-mediated autoimmune disease. Preclinical safety was evaluated in humanized
   mice. Developability was assessed over a four-week stability study.

**Results:**

 ◦ ATG-207 demonstrated a binding preference for TGFβRIII with a KD of 2.42E-06M
   with no detectable binding to TGFβRII in SPR assay. It showed approximately 100-
   fold reduced binding affinity compared to unmasked TGF-β due to the conformationally
   dynamic peptide masking. ATG-207 displayed comparable binding affinity with attenuated
   NFAT-luciferase signaling and reduced proinflammatory cytokine production in 
   whole blood compared to the parental anti-CD3 antibody. In addition, ATG-207 
   effectively downregulated surface T cell receptor (TCR) expression on T cells.
   ATG-207 induced stronger TGF-β pathway activation, as measured by p-SMAD signaling,
   in T cells compared with CD3-negative cells. Importantly, ATG-207 potently induced
   regulatory T cells in _ex vivo_ studies using T cells isolated from healthy donors
   or SLE patients.
 ◦ _In vivo_, mouse surrogate ATG-207 exhibited robust therapeutic efficacy in an
   experimental autoimmune encephalomyelitis (EAE) mouse model, collagen-induced
   arthritis (CIA) model and adoptive T cell transfer colitis model. ATG-207 potently
   induced Treg in CD3 humanized mice _in vivo_. In a repeat-dose mouse toxicology
   study, both ATG-207 and its mouse surrogate were well tolerated. ATG-207 demonstrated
   favorable stability under multiple stress conditions.

**Conclusion: **ATG-207 combines CD3-mediated T cell modulation with TGFβRIII-biased
TGF-β signaling to suppress pathogenic T cells while promoting regulatory T cell
differentiation. These preclinical findings support receptor-biased, context-restricted
TGF-β delivery as a potential strategy for durable immune tolerance restoration 
in T cell–mediated autoimmune diseases.

**About Antengene**

Antengene Corporation Limited (**"Antengene"**, SEHK: 6996.HK) is a global, R&D-
driven, commercial-stage biotech company focused on developing first-in-class/best-
in-class therapeutics for diseases with significant unmet medical needs. Its pipeline
spans from preclinical to commercial stages, with key investigational candidates
including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 
x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-
TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed
using Antengene’s proprietary AnTenGager^(®) platform.

AnTenGager^(®), is Antengene’s proprietary TCE 2.0 platform, featuring "2+1" bivalent
binding for low expressing targets, steric hindrance masking, and proprietary CD3
sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) 
and enhance efficacy. These characteristics support the platform’s broad applicability
across autoimmune diseases, solid tumors and hematological malignancies, with programs
targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered 
with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with
K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological
tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (
ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for 
multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic 
myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 35 investigational new drug (IND) approvals in the
U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific
markets. Its lead commercial asset, XPOVIO^(®) (selinexor), is approved in the Mainland
of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia,
Thailand, Indonesia and Australia, and has been included in the national insurance
schemes in five of these markets (Mainland of China, Taiwan China, Australia, South
Korea and Singapore).

**Forward-looking statements**

The forward-looking statements made in this article relate only to the events or
information as of the date on which the statements are made in this article. Except
as required by law, we undertake no obligation to update or revise publicly any 
forward-looking statements, whether as a result of new information, future events
or otherwise, after the date on which the statements are made or to reflect the 
occurrence of unanticipated events. You should read this article completely and 
with the understanding that our actual future results or performance may be materially
different from what we expect. In this article, statements of, or references to,
our intentions or those of any of our Directors or our Company are made as of the
date of this article. Any of these intentions may alter in light of future development.
For a further discussion of these and other factors that could cause future results
to differ materially from any forward-looking statement, please see the other risks
and uncertainties described in the Company’s Annual Report for the year ended December
31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

PR / IR Contacts: 
Peter QianE-mail: [peter.qian@antengene.com](https://www.thailand-business-news.com/pr-news/peter.qian@antengene.com)

BD Contacts:
Ariel GuoE-mail: [ariel.guo@antengene.com](https://www.thailand-business-news.com/pr-news/ariel.guo@antengene.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026 ](http://www.prnasia.com/story/archive/5057714_AE57714_0?rand=184833)